Hailin

Hailin (Suzhou) Pharmaceutical is an innovative biotechnology company based in Suzhou, China, specializing in the discovery and development of next-generation small molecule therapeutics for oncology. The company's primary focus is on overcoming drug resistance in cancer treatment, particularly through the development of fourth-generation EGFR inhibitors. Its lead candidate, HL-001, is designed to target the EGFR C797S mutation, a common resistance mechanism in non-small cell lung cancer patients treated with third-generation inhibitors like osimertinib. Founded by experienced pharmaceutical researchers, Hailin aims to provide high-quality, effective treatment options for patients with unmet medical needs in the field of precision medicine.